Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oaktree Acquisition Corp II Cl A
(NY:
OACB
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Jun 15, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
9.380 (3)
Ask (Size)
12.89 (5)
Prev. Close
9.380
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
June 07, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech
June 03, 2022
From
Oaktree Acquisition Corp. II
Via
Business Wire
Performance
More News
Read More
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
May 24, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
Via
Benzinga
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
May 16, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
May 11, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
April 19, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
April 06, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
March 21, 2022
Via
Benzinga
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
March 09, 2022
Via
Benzinga
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
January 18, 2022
From
Alvotech Holdings S.A.
Via
Business Wire
Biosimilar Player Alvotech To Go Public Via $2.5B Oaktree SPAC Merger
December 08, 2021
Via
Benzinga
Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
December 07, 2021
From
Alvotech Holdings S.A.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.